{"id":"osteoanabolic-therapy","_chembl":null,"_dailymed":null,"mechanism":{"explanation":"Osteoanabolic agents work by enhancing the activity of osteoblasts, the cells responsible for building new bone tissue. Unlike antiresorptive therapies that prevent bone breakdown, osteoanabolic treatments actively promote bone formation and increase bone mineral density.","oneSentence":"Stimulates new bone formation by promoting osteoblast activity and bone matrix synthesis."},"_scrapedAt":"2026-03-28T01:25:01.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122727,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"teriparatide","brand":"Forteo","company":"Eli Lilly","rationale":"Recombinant PTH analog that stimulates bone formation"},{"name":"abaloparatide","brand":"Tymlos","company":"Radius Health","rationale":"PTH-related protein analog with osteoanabolic effects"},{"name":"romosozumab","brand":"Evenity","company":"Amgen","rationale":"Sclerostin inhibitor that increases bone formation"}],"description":"Osteoanabolic therapy refers to a class of treatments that stimulate bone formation rather than simply preventing bone loss. These therapies are being investigated for osteoporosis and bone-related conditions, with research conducted at institutions including the University of Zurich.","indications":{"approved":[{"status":"investigational","condition":"Osteoporosis","patientPopulation":"Adult patients at high risk for fracture"}]},"trialDetails":[{"nctId":"NCT06164795","phase":"","title":"Sequential Therapies After Osteoanabolic Treatment","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-25","conditions":"Osteoporosis, Postmenopausal","enrollment":150},{"nctId":"NCT05264610","phase":"","title":"Retrospective Analysis of the Effects of Perioperative Osteoanabolic Treatment on Patients With Spinal (Fusion) Surgery.","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-07-20","conditions":"Spinal (Fusion) Surgery","enrollment":40},{"nctId":"NCT03472846","phase":"PHASE4","title":"MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-03-01","conditions":"Postmenopausal Osteoporosis, Diabetes Type 2","enrollment":26},{"nctId":"NCT01801397","phase":"PHASE3","title":"A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2014-03","conditions":"Low Bone Mass in Anorexia Nervosa Patients","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"osteoanabolic therapy","genericName":"osteoanabolic therapy","companyName":"University of Zurich","companyId":"university-of-zurich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}